Iana H Haralambieva1, Hannah M Salk2, Nathaniel D Lambert1, Inna G Ovsyannikova1, Richard B Kennedy1, Nathaniel D Warner3, V Shane Pankratz3, Gregory A Poland4. 1. Mayo Vaccine Research Group, Mayo Vaccine Research Group, Mayo Clinic, Guggenheim 611C, 200 First Street SW, Rochester, MN 55905, United States; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, United States. 2. Mayo Vaccine Research Group, Mayo Vaccine Research Group, Mayo Clinic, Guggenheim 611C, 200 First Street SW, Rochester, MN 55905, United States. 3. Division of Biostatistics, Mayo Clinic, Rochester, MN 55905, United States. 4. Mayo Vaccine Research Group, Mayo Vaccine Research Group, Mayo Clinic, Guggenheim 611C, 200 First Street SW, Rochester, MN 55905, United States; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, United States; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: poland.gregory@mayo.edu.
Abstract
INTRODUCTION: Immune response variations after vaccination are influenced by host genetic factors and demographic variables, such as race, ethnicity and sex. The latter have not been systematically studied in regard to live rubella vaccine, but are of interest for developing next generation vaccines for diverse populations, for predicting immune responses after vaccination, and for better understanding the variables that impact immune response. METHODS: We assessed associations between demographic variables, including race, ethnicity and sex, and rubella-specific neutralizing antibody levels and secreted cytokines (IFNγ, IL-6) in two independent cohorts (1994 subjects), using linear and linear mixed models approaches, and genetically defined racial and ethnic categorizations. RESULTS: Our replicated findings in two independent, large, racially diverse cohorts indicate that individuals of African descent have significantly higher rubella-specific neutralizing antibody levels compared to individuals of European descent and/or Hispanic ethnicity (p<0.001). CONCLUSION: Our study provides consistent evidence for racial/ethnic differences in humoral immune response following rubella vaccination.
INTRODUCTION: Immune response variations after vaccination are influenced by host genetic factors and demographic variables, such as race, ethnicity and sex. The latter have not been systematically studied in regard to live rubella vaccine, but are of interest for developing next generation vaccines for diverse populations, for predicting immune responses after vaccination, and for better understanding the variables that impact immune response. METHODS: We assessed associations between demographic variables, including race, ethnicity and sex, and rubella-specific neutralizing antibody levels and secreted cytokines (IFNγ, IL-6) in two independent cohorts (1994 subjects), using linear and linear mixed models approaches, and genetically defined racial and ethnic categorizations. RESULTS: Our replicated findings in two independent, large, racially diverse cohorts indicate that individuals of African descent have significantly higher rubella-specific neutralizing antibody levels compared to individuals of European descent and/or Hispanic ethnicity (p<0.001). CONCLUSION: Our study provides consistent evidence for racial/ethnic differences in humoral immune response following rubella vaccination.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Inna G Ovsyannikova; Robert M Jacobson; Robert A Vierkant; Steven J Jacobsen; V Shane Pankratz; Gregory A Poland Journal: J Infect Dis Date: 2005-01-14 Impact factor: 5.226
Authors: C Christy; M E Pichichero; G F Reed; M D Decker; E L Anderson; M B Rennels; J A Englund; K M Edwards; M C Steinhoff Journal: Pediatrics Date: 1995-09 Impact factor: 7.124
Authors: A Domínguez; P Plans; J Costa; N Torner; N Cardenosa; J Batalla; A Plasencia; L Salleras Journal: Eur J Clin Microbiol Infect Dis Date: 2006-05 Impact factor: 3.267
Authors: Inna G Ovsyannikova; Robert M Jacobson; Robert A Vierkant; Steven J Jacobsen; V Shane Pankratz; Gregory A Poland Journal: Hum Immunol Date: 2004-12 Impact factor: 2.850
Authors: David C Montefiori; Barbara Metch; M Juliana McElrath; Steve Self; Kent J Weinhold; Lawrence Corey Journal: J Infect Dis Date: 2004-10-28 Impact factor: 5.226
Authors: George K Siberry; Kunjal Patel; William J Bellini; Brad Karalius; Murli U Purswani; Sandra K Burchett; William A Meyer; Sun Bae Sowers; Angela Ellis; Russell B Van Dyke Journal: Clin Infect Dis Date: 2015-06-09 Impact factor: 9.079
Authors: Emily A Voigt; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Beth R Larrabee; Daniel J Schaid; Gregory A Poland Journal: Vaccine Date: 2016-08-30 Impact factor: 3.641
Authors: Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Krista M Goergen; Diane E Grill; Min-Hsin Chen; Lijuan Hao; Joseph Icenogle; Gregory A Poland Journal: Vaccine Date: 2019-11-12 Impact factor: 3.641
Authors: Richard B Kennedy; Inna G Ovsyannikova; Antonia Thomas; Beth R Larrabee; Steven Rubin; Gregory A Poland Journal: Vaccine Date: 2019-02-20 Impact factor: 3.641
Authors: Ayako Suzuki; Huiman Barnhart; Jiezhun Gu; Herbert L Bonkovsky; Hans L Tillmann; Robert J Fontana; David E Kleiner Journal: Liver Int Date: 2017-03-02 Impact factor: 5.828
Authors: Stephen N Crooke; Marguerite M Riggenbach; Inna G Ovsyannikova; Nathaniel D Warner; Min-Hsin Chen; Lijuan Hao; Joseph P Icenogle; Gregory A Poland; Richard B Kennedy Journal: Vaccine Date: 2020-11-12 Impact factor: 3.641
Authors: Laura K Boelsen; Eileen M Dunne; Karen E Lamb; Kathryn Bright; Yin Bun Cheung; Lisi Tikoduadua; Fiona M Russell; E Kim Mulholland; Paul V Licciardi; Catherine Satzke Journal: Vaccine Date: 2015-07-29 Impact factor: 3.641